Paratek is working with Allergan to develop an antibiotic to treat acne: Seysara™ (sarecycline)
Seysara™ a new antibiotic for the treatment of moderate to severe acne vulgaris in patients nine years of age and older. Seysara™ is a once-daily, oral, narrow spectrum, tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting.
A New Drug Application for Seysara™ is currently under review by the U.S. Food & Drug Administration based on the positive results of two identical Phase 3 registration studies. If approved, Seysara™ will be commercialized by Allergan in the U.S.
Paratek has retained rest of world (outside of the U.S.) rights to Seysara™ and is currently exploring partnership opportunities to develop and approve Seysara™ in appropriate markets.
This profile has the potential to provide a best in class acne and rosacea treatment.
Seysara™ has been specifically designed to provide:
- Narrow spectrum of activity targeting acne and rosacea specific pathogens (P. acnes, staphylococcus aureus)
- Limited activity against aerobic gram-negative gastrointestinal organisms compared to minocycline and doxycycline
- Demonstrated anti-inflammatory activity
- Long half-life enabling true once-a-day dosing